Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis

Armstrong, 2014, Extra-hepatic complications of nonalcoholic fatty liver disease, Hepatology, 59, 1174, 10.1002/hep.26717 Sanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis, Hepatology, 54, 344, 10.1002/hep.24376 Marchesini, 2001, Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844 Lomonaco, 2012, Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease, Hepatology, 55, 1389, 10.1002/hep.25539 Musso, 2012, Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism, Hepatology, 56, 933, 10.1002/hep.25739 Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621 Lambert, 2014, Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease, Gastroenterology, 146, 726, 10.1053/j.gastro.2013.11.049 Cusi, 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, e6, 10.1053/j.gastro.2012.02.003 Armstrong, 2013, Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program, Aliment Pharmacol Ther, 37, 234, 10.1111/apt.12149 Ben-Shlomo, 2011, Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase, J Hepatol, 54, 1214, 10.1016/j.jhep.2010.09.032 Sharma, 2011, GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy, PLoS One, 6, e25269, 10.1371/journal.pone.0025269 Shirakawa, 2011, Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice, Diabetes, 60, 1246, 10.2337/db10-1338 Mells, 2012, Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet, Am J Physiol Gastrointest Liver Physiol, 302, G225, 10.1152/ajpgi.00274.2011 Ding, 2006, Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice, Hepatology, 43, 173, 10.1002/hep.21006 Lee, 2012, Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice, PLoS One, 7, e31394, 10.1371/journal.pone.0031394 Trevaskis, 2012, Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice, Am J Physiol Gastrointest Liver Physiol, 302, G762, 10.1152/ajpgi.00476.2011 Lee, 2007, Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis, Diabetes, 56, 1671, 10.2337/db06-1182 Zhang, 2013, GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK, Liver Int, 33, 794, 10.1111/liv.12120 D’Alessio, 1994, Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal, J Clin Invest, 93, 2263, 10.1172/JCI117225 Zander, 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study, Lancet, 359, 824, 10.1016/S0140-6736(02)07952-7 Prigeon, 2003, Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect, Am J Physiol Endocrinol Metab, 285, E701, 10.1152/ajpendo.00024.2003 Orskov, 1996, GLP-1 does not acutely affect insulin sensitivity in healthy man, Diabetologia, 39, 1227, 10.1007/BF02658511 Armstrong, 2013, Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial, BMJ Open, 3, e003995, 10.1136/bmjopen-2013-003995 Armstrong, 2014, Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis, Diabetes Obes Metab, 16, 651, 10.1111/dom.12272 Hazlehurst, 2013, Glucocorticoids fail to cause insulin resistance in human subcutaneous adipose tissue in vivo, J Clin Endocrinol Metab, 98, 1631, 10.1210/jc.2012-3523 Gathercole, 2011, Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue, PLoS One, 6, e26223, 10.1371/journal.pone.0026223 Seghieri, 2013, Direct effect of GLP-1 infusion on endogenous glucose production in humans, Diabetologia, 56, 156, 10.1007/s00125-012-2738-3 Gutniak, 1992, Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus, N Engl J Med, 326, 1316, 10.1056/NEJM199205143262003 Toft-Nielson, 1996, The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones, Diabetes, 45, 552, 10.2337/diab.45.5.552 Gedulin, 2005, Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight, Endocrinology, 146, 2069, 10.1210/en.2004-1349 Svegliati-Baroni, 2011, Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis, Liver Int, 31, 1285, 10.1111/j.1478-3231.2011.02462.x Campbell, 2013, Pharmacology, physiology, and mechanisms of incretin hormone action, Cell Metab, 17, 819, 10.1016/j.cmet.2013.04.008 Boden, 2006, Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver, Curr Diab Rep, 6, 177, 10.1007/s11892-006-0031-x Gao, 2007, GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes, Endocrine, 32, 90, 10.1007/s12020-007-9011-4 Vendrell, 2011, Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance, Endocrinology, 152, 4072, 10.1210/en.2011-1070 Perea, 1997, GLP-1 (7–36) amide: effects on glucose transport and metabolism in rat adipose tissue, Horm Metab Res, 29, 417, 10.1055/s-2007-979068 Villanueva-Peñacarrillo, 2001, Effect of GLP-1 on lipid metabolism in human adipocytes, Horm Metab Res, 33, 73, 10.1055/s-2001-12428 Gastaldelli, 2009, Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis, Hepatology, 50, 1087, 10.1002/hep.23116 Bertin, 2001, Action of glucagon and glucagon-like peptide-1-(7–36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo, J Clin Endocrinol Metab, 86, 1229 Gastaldelli, 2010, Pioglitazone in the treatment of NASH: the role of adiponectin, Aliment Pharmacol Ther, 32, 769, 10.1111/j.1365-2036.2010.04405.x